Berckmans René J, Nieuwland Rienk, Tak Paul Peter, Böing Anita N, Romijn Fred P H T M, Kraan Maarten C, Breedveld Ferdinand C, Hack C Erik, Sturk Augueste
Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Arthritis Rheum. 2002 Nov;46(11):2857-66. doi: 10.1002/art.10587.
To determine the cellular origin of synovial microparticles, their procoagulant properties, and their relationship to local hypercoagulation.
Microparticles in synovial fluid and plasma from patients with rheumatoid arthritis (RA; n = 10) and patients with other forms of arthritis (non-RA; n = 10) and in plasma from healthy subjects (n = 20) were isolated by centrifugation. Microparticles were identified by flow cytometry. The ability of microparticles to support coagulation was determined in normal plasma. Concentrations of prothrombin fragment F(1+2) (by enzyme-linked immunosorbent assay [ELISA]) and thrombin-antithrombin (TAT) complexes (by ELISA) were determined as estimates of the coagulation activation status in vivo.
Plasma from patients and healthy controls contained comparable numbers of microparticles, which originated from platelets and erythrocytes. Synovial microparticles from RA patients and non-RA patients originated mainly from monocytes and granulocytes; few originated from platelets and erythrocytes. Synovial microparticles bound less annexin V (which binds to negatively charged phospholipids) than did plasma microparticles, exposed tissue factor, and supported thrombin generation via factor VII. F(1+2) (median 66 nM) and TAT complex (median 710 microg/liter) concentrations were elevated in synovial fluid compared with plasma from the patients (1.6 nM and 7.0 microg/liter, respectively) as well as the controls (1.0 nM and 2.9 microg/liter, respectively).
Synovial fluid contains high numbers of microparticles derived from leukocytes that are strongly coagulant via the factor VII-dependent pathway. We propose that these microparticles contribute to the local hypercoagulation and fibrin deposition in inflamed joints of patients with RA and other arthritic disorders.
确定滑膜微粒的细胞来源、其促凝特性及其与局部高凝状态的关系。
通过离心分离类风湿关节炎患者(RA;n = 10)、其他形式关节炎患者(非RA;n = 10)的滑液和血浆以及健康受试者(n = 20)血浆中的微粒。通过流式细胞术鉴定微粒。在正常血浆中测定微粒支持凝血的能力。测定凝血酶原片段F(1+2)(通过酶联免疫吸附测定法[ELISA])和凝血酶 - 抗凝血酶(TAT)复合物(通过ELISA)的浓度,以评估体内凝血激活状态。
患者血浆和健康对照血浆中含有数量相当的微粒,这些微粒来源于血小板和红细胞。RA患者和非RA患者的滑膜微粒主要来源于单核细胞和粒细胞;很少来源于血小板和红细胞。滑膜微粒比血浆微粒结合更少的膜联蛋白V(其与带负电荷的磷脂结合),暴露组织因子,并通过因子VII支持凝血酶生成。与患者血浆(分别为1.6 nM和7.0 μg/升)以及对照血浆(分别为1.0 nM和2.9 μg/升)相比,滑液中F(1+2)(中位数66 nM)和TAT复合物(中位数710 μg/升)浓度升高。
滑液中含有大量源自白细胞的微粒,这些微粒通过因子VII依赖途径具有很强的促凝作用。我们认为这些微粒促成了RA和其他关节炎疾病患者炎症关节中的局部高凝状态和纤维蛋白沉积。